- List
- By Topic
- On Map
- Search Details

"beta thalassemia"
Need help? See RSS Feeds
Choose a feed type:

"beta thalassemia" (163 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03351829 | Not yet recruiting | Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector |
|
|
Interventional | Not Applicable |
|
Other |
|
|
20 | All | 4 Years to 70 Years (Child, Adult, Senior) | NCT03351829 | GIMI-IRB-17008 | December 1, 2017 | January 1, 2019 | December 31, 2020 | November 24, 2017 | November 30, 2017 |
|
||
2 | NCT02453477 | Recruiting | Gene Therapy for Transfusion Dependent Beta-thalassemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
10 | All | 3 Years to 64 Years (Child, Adult) | NCT02453477 | 2014-004860-39 (EudraCT) | TIGET-BTHAL | May 2015 | August 2019 | August 2019 | May 25, 2015 | February 21, 2018 |
|
|
3 | NCT03275051 | Recruiting | Long-term Safety and Efficacy Follow-up of Subjects Treated With GSK2696277 for Transfusion Dependent Beta-thalassemia in San Raffaele Telethon Institute of Gene Therapy-Beta Thalassemia (TIGET-BTHAL) Study |
|
|
Interventional | Phase 2 |
|
Industry / Other |
|
|
10 | All | 3 Years and older (Child, Adult, Senior) | NCT03275051 | 207757 | October 4, 2017 | May 1, 2026 | May 1, 2026 | September 7, 2017 | October 17, 2017 |
|
||
4 | NCT03276455 | Not yet recruiting | Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
10 | All | 8 Years and older (Child, Adult, Senior) | NCT03276455 | NanFangHospital | September 15, 2017 | September 15, 2020 | September 15, 2021 | September 8, 2017 | September 8, 2017 |
|
||
5 | NCT02626689 | Completed | To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care |
|
|
Observational |
|
Industry |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT02626689 | ACE-536-B-THAL-003 | March 1, 2016 | January 3, 2017 | January 3, 2017 | December 10, 2015 | April 7, 2017 |
|
|||
6 | NCT03358498 | Not yet recruiting | Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox |
|
|
Observational |
|
Other |
|
|
75 | All | 16 Years to 65 Years (Child, Adult) | NCT03358498 | QOLATSIBTPRD | December 1, 2017 | December 1, 2018 | March 1, 2020 | November 30, 2017 | November 30, 2017 |
|
|||
7 | NCT02950857 | Not yet recruiting | A Study of EPEG in Beta Thalassemia Patients |
|
|
Interventional | Phase 1 |
|
Other |
|
|
6 | All | 18 Years to 65 Years (Adult) | NCT02950857 | PETH-001 | December 2016 | May 2017 | June 2017 | November 1, 2016 | November 1, 2016 |
|
||
8 | NCT01206075 | Completed | Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major |
|
|
Interventional | Not Applicable |
|
Other / NIH / Industry |
|
|
20 | All | 18 Years to 50 Years (Adult) | NCT01206075 | 36078-B P01HL053750 2P01HL053750 |
October 2010 | December 2012 | December 2014 | September 21, 2010 | December 30, 2014 |
|
||
9 | NCT02597595 | Active, not recruiting | Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major |
|
|
Interventional | Not Applicable |
|
Other |
|
|
60 | All | 4 Years to 18 Years (Child, Adult) | NCT02597595 | 2771/09/14 | November 2014 | October 2017 | October 2017 | November 5, 2015 | April 28, 2017 |
|
||
10 | NCT03207009 | Recruiting | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
15 | All | up to 50 Years (Child, Adult) | NCT03207009 | HGB-212 | June 8, 2017 | April 2021 | April 2021 | July 2, 2017 | February 7, 2018 |
|
||
11 | NCT02268409 | Active, not recruiting | ACE-536 Extension Study - Beta Thalassemia |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
64 | All | 18 Years and older (Adult, Senior) | NCT02268409 | A536-06 | November 2014 | February 2021 | April 2021 | October 20, 2014 | January 9, 2018 |
|
||
12 | NCT01642758 | Completed | Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
10 | All | 16 Years to 50 Years (Child, Adult) | NCT01642758 | HQK-P2-THAL | LB-04-THAL | May 2012 | November 2012 | January 2013 | July 17, 2012 | March 14, 2013 |
|
|
13 | NCT02906202 | Recruiting | A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
23 | All | up to 50 Years (Child, Adult) | NCT02906202 | HGB-207 | July 2016 | January 2020 | January 2020 | September 20, 2016 | February 28, 2018 |
|
||
14 | NCT03432364 | Recruiting | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
6 | All | 18 Years to 40 Years (Adult) | NCT03432364 | ST-400-01 | March 2018 | May 2020 | May 2022 | February 14, 2018 | March 29, 2018 |
|
||
15 | NCT03101423 | Recruiting | Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism |
|
|
Interventional | Not Applicable |
|
Other |
|
|
10 | All | Child, Adult, Senior | NCT03101423 | LBo | August 1, 2016 | December 31, 2017 | December 31, 2017 | April 5, 2017 | May 9, 2017 |
|
||
16 | NCT01745120 | Completed | A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
18 | All | 12 Years to 35 Years (Child, Adult) | NCT01745120 | HGB-204 | August 2013 | February 8, 2018 | February 21, 2018 | December 7, 2012 | March 30, 2018 |
|
||
17 | NCT02173951 | Unknown † | An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients |
|
|
Interventional | Phase 2 Phase 3 |
|
Other |
|
|
64 | All | 6 Months to 36 Months (Child) | NCT02173951 | start of ICT in young BTM | July 2014 | July 2015 | July 2015 | June 25, 2014 | January 14, 2015 |
|
||
18 | NCT00336362 | Completed | Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major |
|
|
Interventional | Not Applicable |
|
Other / NIH |
|
|
26 | All | 18 Years to 50 Years (Adult) | NCT00336362 | 464 2U01HL066947 IRB no. 27527 EudraCT no. 2005-000315-10 |
July 2006 | August 2010 | August 2010 | June 13, 2006 | December 20, 2012 |
|
||
19 | NCT03381833 | Recruiting | A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
100 | All | 18 Years and older (Adult, Senior) | NCT03381833 | LJ401-BT01 | November 30, 2017 | October 2019 | May 2020 | December 22, 2017 | December 26, 2017 |
|
||
20 | NCT00069862 | Completed | Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
25 | All | 18 Years and older (Adult, Senior) | NCT00069862 | GTC-134-102 | September 2003 | November 2005 | October 3, 2003 | March 5, 2015 |
|
|||
21 | NCT01609595 | Completed | Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand |
|
|
Interventional | Phase 2 |
|
Other |
|
|
10 | All | 18 Years to 55 Years (Adult) | NCT01609595 | ST20-P2T HQK-1001-Thal P2 |
ST20-P2T | March 2012 | November 2012 | December 2012 | June 1, 2012 | March 13, 2013 |
|
|
22 | NCT01724138 | Withdrawn | An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
0 | All | 2 Years to 71 Years (Child, Adult, Senior) | NCT01724138 | CICL670ACN02 | MACS2163 | June 2013 | April 2014 | October 2014 | November 9, 2012 | April 20, 2017 | ||
23 | NCT00790127 | Completed | Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
21 | All | 12 Years to 60 Years (Child, Adult) | NCT00790127 | HQP-2008-003b | March 2009 | May 2010 | May 2010 | November 13, 2008 | May 20, 2011 |
|
||
24 | NCT02671695 | Active, not recruiting | Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia |
|
|
Interventional | Not Applicable |
|
Other |
|
|
40 | All | 8 Years to 18 Years (Child, Adult) | NCT02671695 | 22/03/15 | April 2015 | April 2018 | April 2018 | February 2, 2016 | October 17, 2017 |
|
||
25 | NCT00159042 | Completed | Genetic Factors Affecting the Severity of Beta Thalassemia |
|
Observational |
|
Other |
|
50 | All | Child, Adult, Senior | NCT00159042 | 302803-HMO-CTIL | July 2004 | July 1, 2017 | July 1, 2017 | September 12, 2005 | August 10, 2017 |
|
|||||
26 | NCT02816957 | Recruiting | Benefits of Nigella Sativa in Children With Beta Thalassemia Major |
|
|
Interventional | Early Phase 1 |
|
Other |
|
|
80 | All | 3 Years to 18 Years (Child, Adult) | NCT02816957 | 30794l03l16 | Nigella | June 2016 | June 2017 | June 2017 | June 29, 2016 | April 26, 2017 |
|
|
27 | NCT02342145 | Recruiting | Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major |
|
|
Interventional | Phase 4 |
|
Other |
|
|
40 | All | 2 Years to 18 Years (Child, Adult) | NCT02342145 | gxmuh-2014-14 | June 2014 | June 2016 | December 2018 | January 19, 2015 | January 19, 2015 |
|
||
28 | NCT03462784 | Not yet recruiting | Complications in Children With B- Thalassemia Major |
|
|
Observational |
|
Other |
|
|
201 | All | 1 Year to 18 Years (Child, Adult) | NCT03462784 | Prev TM | May 1, 2018 | March 1, 2019 | October 1, 2019 | March 13, 2018 | March 13, 2018 | ||||
29 | NCT00809042 | Completed | Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia |
|
|
Interventional | Phase 2 |
|
Other |
|
|
120 | All | 4 Years to 35 Years (Child, Adult) | NCT00809042 | SHaghpanah 3342 |
June 2007 | November 2007 | December 2007 | December 16, 2008 | December 16, 2008 |
|
||
30 | NCT00171210 | Completed Has Results |
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
506 | All | 2 Years and older (Child, Adult, Senior) | NCT00171210 | CICL670A0107E1 | October 2004 | April 2008 | September 15, 2005 | May 30, 2011 | May 2, 2011 |
|
||
31 | NCT00103753 | Unknown † | Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major |
|
|
Interventional | Phase 4 |
|
Other / Industry |
|
|
65 | All | 18 Years and older (Adult, Senior) | NCT00103753 | 02 065 | May 2004 | June 2005 | February 15, 2005 | June 24, 2005 |
|
|||
32 | NCT03183375 | Recruiting | The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan |
|
|
Interventional | Phase 2 |
|
Other |
|
|
100 | All | 6 Months and older (Child, Adult, Senior) | NCT03183375 | ERB0002 | August 21, 2017 | April 30, 2018 | June 30, 2018 | June 12, 2017 | September 20, 2017 |
|
||
33 | NCT02307786 | Unknown † | Long Term Outcomes in β Thalassemia Major |
|
Observational |
|
Other |
|
|
150 | All | up to 30 Years (Child, Adult) | NCT02307786 | SCT 0414B | June 2014 | June 2016 | June 2016 | December 4, 2014 | December 4, 2014 |
|
||||
34 | NCT03271541 | Recruiting | A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
24 | All | 18 Years to 55 Years (Adult) | NCT03271541 | BP39642 2016-004799-23 |
October 26, 2017 | August 31, 2019 | October 2, 2019 | September 5, 2017 | April 17, 2018 |
|
||
35 | NCT00061750 | Completed | Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
595 | All | 2 Years and older (Child, Adult, Senior) | NCT00061750 | CICL670A0107 | May 2003 | November 2004 | June 4, 2003 | April 19, 2012 |
|
|||
36 | NCT02984475 | Recruiting | The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major |
|
|
Interventional | Phase 4 |
|
Other |
|
|
60 | All | 11 Years to 18 Years (Child, Adult) | NCT02984475 | CL 1726 | December 2016 | June 2018 | December 2018 | December 7, 2016 | January 29, 2018 |
|
||
37 | NCT01749540 | Completed | Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
64 | All | 18 Years and older (Adult, Senior) | NCT01749540 | A536-04 2012-002499-15 |
February 2013 | November 2015 | November 2015 | December 13, 2012 | December 14, 2016 |
|
||
38 | NCT02274233 | Terminated | Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
24 | All | 18 Years and older (Adult, Senior) | NCT02274233 | SP-420-702 | October 2014 | September 2015 | September 2015 | October 24, 2014 | September 29, 2015 |
|
||
39 | NCT00560820 | Completed | Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
11 | All | 18 Years and older (Adult, Senior) | NCT00560820 | CICL670A2123 2006-006838-17 |
September 2007 | April 2012 | April 2012 | November 20, 2007 | June 20, 2016 |
|
||
40 | NCT00658385 | Completed Has Results |
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major |
|
|
Interventional | Not Applicable |
|
Other |
|
|
5 | All | 18 Years and older (Adult, Senior) | NCT00658385 | 08-030 | April 2008 | February 2011 | February 2011 | April 15, 2008 | November 25, 2016 | November 25, 2016 |
|
|
41 | NCT00447694 | Completed | Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
30 | All | 10 Years and older (Child, Adult, Senior) | NCT00447694 | CICL670AUS04 | February 2006 | November 2009 | November 2009 | March 15, 2007 | September 23, 2016 |
|
||
42 | NCT00171171 | Completed | A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
252 | All | 2 Years and older (Child, Adult, Senior) | NCT00171171 | CICL670A2402 | May 2004 | November 2006 | September 15, 2005 | March 1, 2017 |
|
|||
43 | NCT02151526 | Active, not recruiting | A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
7 | All | 5 Years to 35 Years (Child, Adult) | NCT02151526 | HGB-205 2012-000695-42 |
July 2013 | February 2019 | February 2019 | May 30, 2014 | December 18, 2017 |
|
||
44 | NCT01459718 | Completed | Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
32 | All | 18 Years and older (Adult, Senior) | NCT01459718 | CICL670AGR02 2009-018091-34 |
MACS1097 | January 2011 | June 2014 | June 2014 | October 26, 2011 | February 10, 2015 |
|
|
45 | NCT00001958 | Completed | Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia) |
|
|
Interventional | Phase 2 |
|
NIH |
|
100 | All | Child, Adult, Senior | NCT00001958 | 000040 00-DK-0040 |
December 1999 | February 2002 | January 19, 2000 | March 4, 2008 |
|
||||
46 | NCT01284738 | Completed | Beta-thalassemia and Microparticles |
|
|
Interventional | Not Applicable |
|
Other |
|
|
33 | All | 15 Years and older (Child, Adult, Senior) | NCT01284738 | 2010-A00198-31 2009-18 |
March 2010 | February 2014 | January 27, 2011 | August 29, 2014 |
|
|||
47 | NCT01129076 | Completed | Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma |
|
Observational |
|
NIH |
|
30 | All | 14 Years and older (Child, Adult, Senior) | NCT01129076 | 999910104 10-HG-N104 |
April 23, 2010 | January 7, 2016 | May 24, 2010 | April 13, 2018 |
|
||||||
48 | NCT03171831 | Recruiting | Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major |
|
|
Interventional | Phase 4 |
|
Other |
|
|
30 | All | 2 Years to 18 Years (Child, Adult) | NCT03171831 | Guangxi-Haplo-HSCT-2016 | April 1, 2017 | December 31, 2021 | April 1, 2022 | May 31, 2017 | May 31, 2017 |
|
||
49 | NCT03161899 | Not yet recruiting | Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital |
|
Observational |
|
Other |
|
|
246 | All | 6 Years to 14 Years (Child) | NCT03161899 | ENST | October 2017 | May 31, 2018 | December 1, 2018 | May 22, 2017 | July 19, 2017 | |||||
50 | NCT00564941 | Completed | Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload |
|
|
Interventional | Phase 4 |
|
Industry |
|
|
309 | All | 18 Years to 80 Years (Adult, Senior) | NCT00564941 | CICL670AHU02 | December 2007 | July 2011 | July 2011 | November 29, 2007 | February 24, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.